Develops topical pharmaceutical products. Manufactures oral pharmaceutical products. Now — the numbers.
This is an established company with proven profits.
The gap is $1.0M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 0.1× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 1 years, sales grew about 378% a year on average.
The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown.